Myriad Genetics (STU:MYD) Research & Development: €91.4 Mil (TTM As of Mar. 2026)


STU:MYD Myriad Genetics Inc STU:MYD
53 GF Score
Price €5.01
GF Value €12.90
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Myriad Genetics Research & Development?

Myriad Genetics STU:MYD +5.96% 53 Research & Development is €91.4 Mil as of Mar. 2026. GuruFocus rates STU:MYD with a GF Score™ of 53/100 and a GF Value™ of €12.90 (Possible Value Trap). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Myriad Genetics's Research & Development for the three months ended in Mar. 2026 was €23.4 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €91.4 Mil.

Myriad Genetics  (STU:MYD) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Myriad Genetics Research & Development Related Terms

Myriad Genetics Research & Development Historical Data

* Premium members only.

The historical data trend for Myriad Genetics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Myriad Genetics Research & Development Chart

Myriad Genetics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 72.48 80.62 81.34 108.30 91.21

Myriad Genetics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.44 22.20 24.03 21.78 23.44
STU:MYD
53GF Score
Myriad Genetics Inc STU:MYD
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Myriad Genetics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €91.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €91.4 Mil mean?
Myriad Genetics (STU:MYD) has a Research & Development of €91.4 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Myriad Genetics and its competitors.
Is Myriad Genetics' Research & Development too high?
Myriad Genetics' current Research & Development is €91.4 Mil. Overall, Myriad Genetics has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Myriad Genetics' Research & Development compare to PRE and FLGT?
Myriad Genetics' Research & Development of €91.4 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Diagnostics & Research company?
A good Research & Development depends on the Medical Diagnostics & Research industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Myriad Genetics and its competitors. Myriad Genetics's current Research & Development is €91.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Myriad Genetics stock overvalued right now?
Based on GuruFocus' analysis, Myriad Genetics (STU:MYD) is currently considered Possible Value Trap. The stock's GF Value™ is €12.90, compared to a current price of €5.01 — trading 61.1% below its estimated fair value. The current Research & Development is €91.4 Mil. Myriad Genetics' overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Myriad Genetics (STU:MYD), the current Research & Development is €91.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Myriad Genetics (STU:MYD) Overvalued in 2026?

Based on GuruFocus' analysis, Myriad Genetics stock appears to be undervalued. The current stock price of €5.01 is trading 61.1% below its estimated GF Value™ of €12.90. GuruFocus considers Myriad Genetics to be Possible Value Trap.

Key valuation signals for STU:MYD:

  • Research & Development: €91.4 Mil
  • GF Value™: €12.90 vs. price of €5.01 (61.1% below fair value)
  • GF Score™: 53/100 with 5 warning signs

No single metric tells the full story. See the STU:MYD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Myriad Genetics Business Description

Other Exchanges MYGN:USA0K3W:UKMYD:Germany
Address 322 North 2200 West, Salt Lake City, UT, USA, 84116
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
53GF Score

Get the complete analysis for STU:MYD

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.01
Price
€12.90
GF Value